Home » J&J, Pharmacyclics File Breakthrough Drug Ibrutinib
J&J, Pharmacyclics File Breakthrough Drug Ibrutinib
Johnson and Johnson and Pharmacyclics have submitted their blood cancer drug ibrutinib to the FDA for marketing approval for two different types of leukemia.
Pharma Times
Pharma Times
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May